-
Information-Publications
-
Enhancement of prime editing via xrRNA motif-joined pegRNADetails
-
High PKD2 predicts poor prognosis in lung adenocarcinoma via promoting Epithelial–mesenchymal TransitionDetails
-
Gelation of cytoplasmic expanded CAG RNA repeats suppresses global protein synthesisDetails
-
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regenerationDetails
-
Phosphorylated YBX2 is stabilized to promote glycolysis in brown adipocytesDetails
-
Butyrate reverses ferroptosis resistance in colorectal cancer by inducing c-Fos-dependent xCT suppressionDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands